Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

被引:29
|
作者
Hotta, Katsuyuki [1 ]
Fujimoto, Nobukazu [2 ]
机构
[1] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[2] Okayama Rosai Hospitalosai Hosp, Dept Med Oncol & Med, Okayama, Japan
关键词
immunotherapy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; CELL LUNG-CANCER; OPEN-LABEL; PROSPECTIVE FEASIBILITY; DOUBLE-BLIND; SINGLE-ARM; PHASE-III; TREMELIMUMAB; TRIAL;
D O I
10.1136/jitc-2019-000461
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
    Metro, Giulio
    Signorelli, Diego
    Pizzutilo, Elio G.
    Giannetta, Laura
    Cerea, Giulio
    Garaffa, Miriam
    Friedlaender, Alex
    Addeo, Alfredo
    Mandarano, Martina
    Bellezza, Guido
    Roila, Fausto
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (09) : 2972 - 2980
  • [2] The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
    Borgeaud, Maxime
    Kim, Floryane
    Friedlaender, Alex
    Lococo, Filippo
    Addeo, Alfredo
    Minervini, Fabrizio
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
  • [3] Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
    Wanyuan Cui
    Sanjay Popat
    [J]. Drugs, 2021, 81 : 971 - 984
  • [4] Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
    Cui, Wanyuan
    Popat, Sanjay
    [J]. DRUGS, 2021, 81 (09) : 971 - 984
  • [5] Immune checkpoint inhibitors in malignant pleural mesothelioma
    Ceresoli, Giovanni Luca
    Mantovani, Alberto
    [J]. LANCET ONCOLOGY, 2017, 18 (05): : 559 - 561
  • [6] Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
    Yoshikawa, Yoshie
    Kuribayashi, Kozo
    Minami, Toshiyuki
    Ohmuraya, Masaki
    Kijima, Takashi
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Malignant pleural mesothelioma: current and future perspectives
    Porpodis, Konstantinos
    Zarogoulidis, Paul
    Boutsikou, Efimia
    Papaioannou, Antonis
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Zaric, Bojan
    Perin, Branislav
    Huang, Haidong
    Kougioumtzi, Ioanna
    Spyratos, Dionysios
    Zarogoulidis, Konstantinos
    [J]. JOURNAL OF THORACIC DISEASE, 2013, 5 : S397 - S406
  • [8] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    [J]. CANCERS, 2022, 14 (06)
  • [9] Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges
    Ceresoli, Giovanni Luca
    Bonomi, Maria
    Sauta, Maria Grazia
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (07) : 673 - 675
  • [10] Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
    Farina, Antonio
    Escalere, Manon
    Dion, Matthias
    Moussy, Martin
    Pegat, Antoine
    Villagran-Garcia, Macarena
    Devic, Perrine
    Lamiral, Anaide
    Seyve, Antoine
    Aure, Karine
    Wang, Adrien
    Gorza, Lucas
    Streichenberger, Nathalie
    Maisonobe, Thierry
    Honnorat, Jerome
    Birzu, Cristina
    Psimaras, Dimitri
    Weisenburger-Lile, David
    Joubert, Bastien
    [J]. FRONTIERS IN NEUROLOGY, 2024, 15